Table 2.
Clinical characteristics of participants (n=10).
| Characteristics | Value, n (%) | ||
| Cardiovascular disease diagnosis | |||
|
|
Coronary heart disease | 8 (80) | |
|
|
Myocardial infarction | 1 (10) | |
|
|
Congestive heart failure | 1 (10) | |
| Comorbidities | |||
|
|
Diabetes | 3 (30) | |
|
|
Arthritis | 4 (40) | |
|
|
Orthopedic disorder | 2 (20) | |
|
|
Skin cancer | 1 (10) | |
| Cardiovascular risk factors | |||
|
|
Overweight (BMI 25.0-29.9 kg/m2) or obese (BMI >30 kg/m2) | 6 (60) | |
|
|
Familial heart disease (onset before 60 years and 50 years in mother and father, respectively) | 2 (20) | |
|
|
Dyslipidemia | 10 (100) | |
|
|
Hypertension | 6 (60) | |
|
|
Physical inactivity (<30 min 5 times weekly) | 8 (80) | |
| Tobacco use | |||
|
|
Never | 4 (40) | |
|
|
Former | 6 (60) | |
| Medication classes prescribed | |||
|
|
Beta blocker | 8 (80) | |
|
|
Calcium channel blocker | 2 (20) | |
|
|
Angiotensin-converting enzyme inhibitor | 4 (40) | |
|
|
Angiotensin receptor blocker | 3 (30) | |
|
|
Statin | 10 (100) | |
|
|
Insulin | 2 (20) | |
|
|
Metformin | 2 (20) | |
|
|
Aspirin | 9 (90) | |
|
|
Clopidogrel | 5 (50) | |
|
|
Other antiplatelet | 3 (30) | |